Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Plexxikon and Roche in deal to develop polycystic kidney disease therapy
February 2009
SHARING OPTIONS:

BERKELEY, Calif.Plexxikon Inc. and Roche announced last month an agreement to develop and commercialize PLX5568, a small molecule inhibitor of Raf kinase, as an oral therapeutic treatment for polycystic kidney disease (PKD). Under the terms of the agreement, Roche will have a worldwide, exclusive license to develop and commercialize PLX5568, in addition to certain other selective Raf inhibitors resulting from the partnership. In exchange, Roche will pay Plexxikon $60 million upfront and up to $275 million in milestone payments. Plexxikon will also receive royalties for any sales related to products under the collaboration. Currently, there is no registered treatment for PKD, which affects more than 600,000 patients in the United States and is the most common life-threatening genetic disease. DDN
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.